Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 448

1.

Effects of Testosterone on Benign and Malignant Conditions of the Prostate.

Herati AS, Kohn TP, Butler PR, Lipshultz LI.

Curr Sex Health Rep. 2017 Jun;9(2):65-73. doi: 10.1007/s11930-017-0104-7. Epub 2017 Apr 26.

PMID:
29056882
2.

Singapore Urological Association Clinical Guidelines for Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia.

Singapore Urological Association Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Guidelines Committee 2015.

Singapore Med J. 2017 Aug;58(8):473-480. doi: 10.11622/smedj.2017082.

3.

The Modulating Effects of Benign Prostate Enlargement Medications on Upgrading Predictors in Patients with Gleason 6 at Biopsy.

Jazayeri SB, Kwon YS, McBride R, Leapman M, Collingwood S, Hobbs A, Samadi DB.

Curr Urol. 2017 Jul;10(2):97-104. doi: 10.1159/000447159. Epub 2017 May 30.

4.

The impact of finasteride and dutasteride treatments on proliferation, apoptosis, androgen receptor, 5α-reductase 1 and 5α-reductase 2 in TRAMP mouse prostates.

Opoku-Acheampong AB, Henningson JN, Lindshield BL.

Heliyon. 2017 Jul 24;3(7):e00360. doi: 10.1016/j.heliyon.2017.e00360. eCollection 2017 Jul.

5.

Five-Alpha Reductase Inhibitor and Breast Cancer Risk in Men: A Systematic Review.

Kim MW, Park HS, Park JS, Koh SJ, Cho S.

Ann Dermatol. 2017 Aug;29(4):525-528. doi: 10.5021/ad.2017.29.4.525. Epub 2017 Jun 21. No abstract available.

6.

A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts.

Platz EA, Kulac I, Barber JR, Drake CG, Joshu CE, Nelson WG, Lucia MS, Klein EA, Lippman SM, Parnes HL, Thompson IM, Goodman PJ, Tangen CM, De Marzo AM.

Cancer Epidemiol Biomarkers Prev. 2017 Oct;26(10):1549-1557. doi: 10.1158/1055-9965.EPI-17-0503. Epub 2017 Jul 28.

PMID:
28754796
7.

Polyphenolic extract of InsP 5-ptase expressing tomato plants reduce the proliferation of MCF-7 breast cancer cells.

Alimohammadi M, Lahiani MH, McGehee D, Khodakovskaya M.

PLoS One. 2017 Apr 27;12(4):e0175778. doi: 10.1371/journal.pone.0175778. eCollection 2017.

8.

Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial.

Miles FL, Goodman PJ, Tangen C, Torkko KC, Schenk JM, Song X, Pollak M, Thompson IM, Neuhouser ML.

Nutrients. 2017 Apr 12;9(4). pii: E378. doi: 10.3390/nu9040378.

9.

Chemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparison.

Cui K, Li X, Du Y, Tang X, Arai S, Geng Y, Xi Y, Xu H, Zhou Y, Ma W, Zhang T.

Oncotarget. 2017 May 30;8(22):36674-36684. doi: 10.18632/oncotarget.16230.

10.

Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.

Dutta A, Panja S, Virk RK, Kim JY, Zott R, Cremers S, Golombos DM, Liu D, Mosquera JM, Mostaghel EA, Barbieri CE, Mitrofanova A, Abate-Shen C.

Eur Urol. 2017 Oct;72(4):499-506. doi: 10.1016/j.eururo.2017.03.031. Epub 2017 Apr 4.

PMID:
28385453
11.

Relationship Between Alcohol Consumption and Prostatic Hyperplasia According to Facial Flushing After Drinking in Korean Men.

Jang HS, Kim JS, Kim SS, Jung JG, Yoon SJ, Yang H, Joung HC.

Korean J Fam Med. 2017 Mar;38(2):93-98. doi: 10.4082/kjfm.2017.38.2.93. Epub 2017 Mar 22.

12.

Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.

Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL, Thompson IM, Lucia MS, Lippman SM, Parnes HL, Isaacs WB, De Marzo AM, Drake CG, Platz EA.

Prostate. 2017 Jun;77(8):908-919. doi: 10.1002/pros.23346. Epub 2017 Mar 20.

PMID:
28317149
13.

Fatty Acid Synthesis Intermediates Represent Novel Noninvasive Biomarkers of Prostate Cancer Chemoprevention by Phenethyl Isothiocyanate.

Singh KB, Singh SV.

Cancer Prev Res (Phila). 2017 May;10(5):279-289. doi: 10.1158/1940-6207.CAPR-17-0001. Epub 2017 Mar 14.

PMID:
28292742
14.

Astaxanthin Inhibits PC-3 Xenograft Prostate Tumor Growth in Nude Mice.

Ni X, Yu H, Wang S, Zhang C, Shen S.

Mar Drugs. 2017 Mar 8;15(3). pii: E66. doi: 10.3390/md15030066.

15.

Early dutasteride monotherapy in men with detectable serum prostate-specific antigen levels following radical prostatectomy: A prospective trial.

Shin YS, Lee JW, Kim MK, Jeong YB, Park SC.

Investig Clin Urol. 2017 Mar;58(2):98-102. doi: 10.4111/icu.2017.58.2.98. Epub 2017 Feb 15.

16.

Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome.

Fertig R, Shapiro J, Bergfeld W, Tosti A.

Skin Appendage Disord. 2017 Jan;2(3-4):120-129. doi: 10.1159/000450617. Epub 2016 Sep 23. Review.

17.

Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia.

Hagberg KW, Divan HA, Fang SC, Nickel JC, Jick SS.

Clin Epidemiol. 2017 Feb 10;9:83-91. doi: 10.2147/CLEP.S124674. eCollection 2017.

18.

Cancer Prevention: Lessons Learned and Future Directions.

Dunn BK, Kramer BS.

Trends Cancer. 2016 Dec;2(12):713-722. doi: 10.1016/j.trecan.2016.11.003.

PMID:
28138568
19.

Vitamin K epoxide reductase regulation of androgen receptor activity.

Tew BY, Hong TB, Otto-Duessel M, Elix C, Castro E, He M, Wu X, Pal SK, Kalkum M, Jones JO.

Oncotarget. 2017 Feb 21;8(8):13818-13831. doi: 10.18632/oncotarget.14639.

20.

Germline genetic profiling in prostate cancer: latest developments and potential clinical applications.

Ahmed M, Eeles R.

Future Sci OA. 2015 Dec 18;2(1):FSO87. doi: 10.4155/fso.15.87. eCollection 2016 Mar. Review.

Supplemental Content

Support Center